Structure-based drug design of catechol-O-methyltransferase inhibitors for CNS disorders

British Journal of Clinical Pharmacology

Volumn 77, Issue 3, 2014, Pages 410-420

  Ma, Zhiguo ^a   Liu, Hongming ^a   Wu, Baojian ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

catechol O methyltransferase; COMT; crystal structure; drug discovery; drug metabolism

Indexed keywords

CATECHOL-O-METHYLTRANSFERASE; COMT; CRYSTAL STRUCTURE; DRUG DISCOVERY; DRUG METABOLISM;

ANIMALS; BINDING SITES; CATALYTIC DOMAIN; CATECHOL O-METHYLTRANSFERASE; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84894461813     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12169     Document Type: Review

References (46)

1. Männistö PT, Kaakkola S,. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 1999; 51: 593-628.
2. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melén K, Julkunen I, Taskinen J,. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995; 34: 4202-4210.
3. Tenhunen J, Salminen M, Lundström K, Kiviluoto T, Savolainen R, Ulmanen I,. Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. Eur J Biochem 1994; 223: 1049-1059.
4. Karhunen T, Tilgmann C, Ulmanen I, Julkunen I, Panula P,. Distribution of catechol-O-methyltransferase enzyme in rat tissues. J Histochem Cytochem 1994; 42: 1079-1090.
5. Zheng YJ, Bruice TC,. A theoretical examination of the factors controlling the catalytic efficiency of a transmethylation enzyme: catechol O-methyltransferase. J Am Chem Soc 1997; 119: 8137-8145.
6. Tsao D, Diatchenko L, Dokholyan NV,. Structural mechanism of S-adenosyl methionine binding to catechol O-methyltransferase. PLoS ONE 2011; 6: e24287.
7. Guldberg HC, Marsden CA,. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev 1975; 27: 135-206.
8. Kostic̈ VS,. COMT inhibition in the treatment of Parkinson's disease: neuroprotection and future perspectives. Adv Exp Med Biol 2004; 541: 75-90.
9. Sazci A, Ergul E, Kucukali I, Kilic G, Kaya G, Kara I,. Catechol-O-methyltransferase gene Val108/158Met polymorphism, and susceptibility to schizophrenia: association is more significant in women. Brain Res Mol Brain Res 2004; 132: 51-56.
10. Handoko HY, Nyholt DR, Hayward NK, Nertney DA, Hannah DE, Windus LC, McCormack CM, Smith HJ, Filippich C, James MR, Mowry BJ,. Separate and interacting effects within the catechol-O-methyltransferase (COMT) are associated with schizophrenia. Mol Psychiatry 2005; 10: 589-597.
11. Fava M, Rosenbaum JF, Kolsky AR, Alpert JE, Nierenberg AA, Spillmann M, Moore C, Renshaw P, Bottiglieri T, Moroz G, Magni G,. Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. J Clin Psychopharmacol 1999; 19: 329-335.
12. Männistö PT, Ulmanen I, Lundström K, Taskinen J, Tenhunen J, Tilgmann C, Kaakkola S,. Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res 1992; 39: 291-350.
13. Bonifati V, Meco G,. New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease. Pharmacol Ther 1999; 81: 1-36.
14. Martin JL, McMillan FM,. SAM (dependent) I AM: the S-adenosylmethionine- dependent methyltransferase fold. Curr Opin Struct Biol 2002; 12: 783-793.
15. Vidgren J, Svensson LA, Liljas A,. Crystal structure of catechol O-methyltransferase. Nature 1994; 368: 354-358.
16. Rutherford K, Le Trong I, Stenkamp RE, Parson WW,. Crystal structures of human 108V and 108M catechol O-methyltransferase. J Mol Biol 2008; 380: 120-130.
17. Tsuji E, Okazaki K, Takeda K,. Crystal structures of rat catechol-O-methyltransferase complexed with coumarine-based inhibitor. Biochem Biophys Res Commun 2009; 378: 494-497.
18. Tsuji E, Okazaki K, Isaji M, Takeda K,. Crystal structures of the apo and holo form of rat catechol-O-methyltransferase. J Struct Biol 2009; 165: 133-139.
19. Ellermann M, Jakob-Roetne R, Lerner C, Borroni E, Schlatter D, Roth D, Ehler A, Rudolph MG, Diederich F,. Molecular recognition at the active site of catechol-O-methyltransferase: energetically favorable replacement of a water molecule imported by a bisubstrate inhibitor. Angew Chem Int Ed Engl 2009; 48: 9092-9096.
20. Ellermann M, Paulini R, Jakob-Roetne R, Lerner C, Borroni E, Roth D, Ehler A, Schweizer WB, Schlatter D, Rudolph MG, Diederich F,. Molecular recognition at the active site of catechol-O-methyltransferase (COMT): adenine replacements in bisubstrate inhibitors. Chemistry 2011; 17: 6369-6381.
21. Ellermann M, Lerner C, Burgy G, Ehler A, Bissantz C, Jakob-Roetne R, Paulini R, Allemann O, Tissot H, Grünstein D, Stihle M, Diederich F, Rudolph MG,. Catechol-O-methyltransferase in complex with substituted 3′-deoxyribose bisubstrate inhibitors. Acta Crystallogr D Biol Crystallogr 2012; 68: (Pt 3): 253-260.
22. Palma PN, Rodrigues ML, Archer M, Bonifácio MJ, Loureiro AI, Learmonth DA, Carrondo MA, Soares-da-Silva P,. Comparative study of ortho- and meta-nitrated inhibitors of catechol-O-methyltransferase: interactions with the active site and regioselectivity of O-methylation. Mol Pharmacol 2006; 70: 143-153.
23. Bonifácio MJ, Archer M, Rodrigues ML, Matias PM, Learmonth DA, Carrondo MA, Soares-Da-Silva P,. Kinetics and crystal structure of catechol-O-methyltransferase complex with co-substrate and a novel inhibitor with potential therapeutic application. Mol Pharmacol 2002; 62: 795-805.
24. Lerner C, Ruf A, Gramlich V, Masjost B, Zürcher G, Jakob-Roetne R, Borroni E, Diederich F,. X-ray crystal structure of a bisubstrate inhibitor bound to the Enzyme catechol-O-methyltransferase: A dramatic effect of inhibitor preorganization on binding affinity. Angew Chem Int Ed Engl 2001; 40: 4040-4042.
25. Lautala P, Ulmanen I, Taskinen J,. Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase. Mol Pharmacol 2001; 59: 393-402.
26. Bäckström R, Honkanen E, Pippuri A, Kairisalo P, Pystynen J, Heinola K, Nissinen E, Linden IB, Männistö PT, Kaakkola S,. Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors. J Med Chem 1989; 32: 841-846.
27. Piedrafita FJ, Elorriaga C, Fernández-Alvarez E, Nieto O,. Inhibition of catechol-O-methyltransferase by N-(3,4-dihydroxyphenyl) maleimide. J Enzyme Inhib 1990; 4: 43-50.
28. Marsala SZ, Gioulis M, Ceravolo R, Tinazzi M,. A systematic review of catechol-O-methyltransferase inhibitors: efficacy and safety in clinical practice. Clin Neuropharmacol 2012; 35: 185-190.
29. Barrow JC,. Inhibitors of catechol-O-methyltransferase. CNS Neurol Disord Drug Targets 2012; 11: 324-332.
30. Kaakkola S,. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease. Int Rev Neurobiol 2010; 95: 207-225.
31. Learmonth DA, Vieira-Coelho MA, Benes J, Alves PC, Borges N, Freitas AP, da-Silva PS,. Synthesis of 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone and derivatives as potent and long-acting peripheral inhibitors of catechol-O-methyltransferase. J Med Chem 2002; 45: 685-695.
32. Palma PN, Bonifácio MJ, Loureiro AI, Wright LC, Learmonth DA, Soares-da-Silva P,. Molecular modeling and metabolic studies of the interaction of catechol-O-methyltransferase and a new nitrocatechol inhibitor. Drug Metab Dispos 2003; 31: 250-258.
33. Learmonth DA, Palma PN, Vieira-Coelho MA, Soares-da-Silva P,. Synthesis, biological evaluation, and molecular modeling studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem 2004; 47: 6207-6217.
34. Masjost B, Ballmer P, Borroni E, Zürcher G, Winkler FK, Jakob-Roetne R, Diederich F,. Structure-based design, synthesis, and in vitro evaluation of bisubstrate inhibitors for catechol O-methyltransferase (COMT). Chemistry 2000; 6: 971-982.
35. Lerner C, Masjost B, Ruf A, Gramlich V, Jakob-Roetne R, Zürcher G, Borroni E, Diederich F,. Bisubstrate inhibitors for the enzyme catechol-O-methyltransferase (COMT): influence of inhibitor preorganisation and linker length between the two substrate moieties on binding affinity. Org Biomol Chem 2003; 1: 42-49.
36. Paulini R, Lerner C, Jakob-Roetne R, Zürcher G, Borroni E, Diederich F,. Bisubstrate inhibitors of the enzyme catechol O-methyltransferase (COMT): efficient inhibition despite the lack of a nitro group. Chembiochem 2004; 5: 1270-1274.
37. Smith KS, Smith PL, Heady TN, Trugman JM, Harman WD, Macdonald TL,. In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity. Chem Res Toxicol 2003; 16: 123-128.
38. Barillari C, Taylor J, Viner R, Essex JW,. Classification of water molecules in protein binding sites. J Am Chem Soc 2007; 129: 2577-2587.
39. Paulini R, Trindler C, Lerner C, Brändli L, Schweizer WB, Jakob-Roetne R, Zürcher G, Borroni E, Diederich F,. Bisubstrate inhibitors of catechol O-methyltransferase (COMT): the crucial role of the ribose structural unit for inhibitor binding affinity. ChemMedChem 2006; 1: 340-357.
40. Bissantz C, Kuhn B, Stahl M,. A medicinal chemist's guide to molecular interactions. J Med Chem 2010; 53: 5061-5084.
41. Müller K, Faeh C, Diederich F,. Fluorine in pharmaceuticals: looking beyond intuition. Science 2007; 317: 1881-1886.
42. Fisher A, Croft-Baker J, Davis M, Purcell P, McLean AJ,. Entacapone-induced hepatotoxicity and hepatic dysfunction. Mov Disord 2002; 17: 1362-1365.
43. Kiss LE, Ferreira HS, Torrão L, Bonifácio MJ, Palma PN, Soares-da-Silva P, Learmonth DA,. Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem 2010; 53: 3396-3411.
44. Almeida L, Rocha JF, Falcao A, Palma PN, Loureiro AI, Pinto R, Bonifácio MJ, Wright LC, Nunes T, Soares-da-Silva P,. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O- methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. Clin Pharmacokinet 2013; 52: 139-151.
45. Rocha JF, Almeida L, Falcao A, Palma PN, Loureiro AI, Pinto R, Bonifácio MJ, Wright LC, Nunes T, Soares-da-Silva P,. Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol 2013; 76: 763-775.
46. Palma PN, Bonifácio MJ, Loureiro AI, Soares-da-Silva P,. Computation of the binding affinities of catechol-O-methyltransferase inhibitors: multisubstate relative free energy calculations. J Comput Chem 2012; 33: 970-986